Werewolf Therapeutics, Inc. (HOWL) Stock Score, Valuation & Financial Research

Werewolf Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for HOWL

Werewolf Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.92. These figures are a research snapshot, not a buy or sell recommendation.

What Werewolf Therapeutics, Inc. does

Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Werewolf Therapeutics is a biopharmaceutical company that generates revenue primarily through research and development collaborations and licensing agreements. The company leverages its proprietary PREDATOR platform to develop conditionally activated therapeutics, receiving payments such as upfront fees, milestone payments, and potential future royalties from partners.

Products and services

  • The company develops conditionally activated therapeutics, known as INDUKINE molecules, designed to remain inactive in peripheral tissue and activate selectively in the tumor microenvironment to treat cancer.

Brands and product families

  • PREDATOR — Proprietary platform for engineering conditionally activated therapeutics. Source
  • INDUKINE — Molecules engineered to remain inactive in peripheral tissue and activate in the tumor microenvironment. Source

Customer types

Biopharmaceutical companies.

Disclosed major customers

Suppliers, materials and equipment

  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Jazz Pharmaceuticals — A strategic collaboration and license agreement for the development and commercialization of certain product candidates. Source

Competitors and product-market comparisons

  • Biopharmaceutical and biotechnology companies — The company competes with various entities developing cancer immunotherapies and cytokine-based treatments. Source

Business strengths to evaluate

  • Proprietary PREDATOR platform Source
  • INDUKINE molecule technology Source

Business risks and research considerations

  • Dependence on third-party manufacturers Source
  • Clinical trial failure and regulatory uncertainty Source
  • Concentration of revenue from a single partner Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

HOWL financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.92
Market capitalization:
44.72M (currency not supplied)
Revenue:
USD 21M
Net income:
USD -34.61M
Free cash flow:
USD -60.29M
Cash:
USD 21.99M
Total debt:
USD 9.44M
EPS:
USD -0.73

What stands out

  • Free cash flow is USD -60.29M, negative for the stored period.
  • The balance sheet shows USD 21.99M of cash versus USD 9.44M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -287.1% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -164.8% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 12.55M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for HOWL

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can HOWL fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is HOWL likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for HOWL to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of HOWL's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research HOWL

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.